Sam Brusco, Associate Editor11.30.23
Johnson & Johnson MedTech has acquired Laminar, a company focused on eliminated the left atrial appendage (LAA) in non-valvular atrial fibrillation (AFib) patients.
J&J MedTech acquired Laminar for upfront payment of $400 million, with further potential clinical and regulatory and milestone payments in 2024 and beyond. Laminar joins J&J MedTech’s Biosense Webster company.
The LAA is a small pouch in the heart’s left atrium and can be a source of clots that can enter the blood stream, potentially causing a stroke. The LAA is a major contributor to thromboembolic stroke in patients with non-valvular AFib.
Laminar uses rotational motion to eliminate the LAA, unlike current catheter-based procedure devices that use plugs to occlude the LAA. The company recently earned U.S. Food and Drug Administration (FDA) approval for a U.S. pivotal study, which is expected to begin enrolling in 2024.
“For the millions of people living with AFib, stroke risk is a major concern. The team at Laminar is driven by our vision to develop and deliver an innovative solution to help patients live without the fear of stroke, or the need for long-term use of blood thinners,” Randy Lashinski, president and CEO of Laminar told the press. “We are looking forward to advancing this vision as part of Johnson & Johnson MedTech.”
“We are excited to welcome Laminar to Johnson & Johnson MedTech,” added Jasmina Brooks, president of Biosense Webster. “Laminar’s innovative approach will provide Biosense Webster the opportunity to expand our portfolio in this high growth market, complement our electrophysiology and Intracardiac Echo strengths, and deepen our presence with interventional cardiologists and electrophysiologists. Fueled by the global scale and commercial and clinical strength of Biosense Webster, we are excited to explore the possibilities ahead to reach even more patients with critical unmet need.”
J&J MedTech acquired Laminar for upfront payment of $400 million, with further potential clinical and regulatory and milestone payments in 2024 and beyond. Laminar joins J&J MedTech’s Biosense Webster company.
The LAA is a small pouch in the heart’s left atrium and can be a source of clots that can enter the blood stream, potentially causing a stroke. The LAA is a major contributor to thromboembolic stroke in patients with non-valvular AFib.
Laminar uses rotational motion to eliminate the LAA, unlike current catheter-based procedure devices that use plugs to occlude the LAA. The company recently earned U.S. Food and Drug Administration (FDA) approval for a U.S. pivotal study, which is expected to begin enrolling in 2024.
“For the millions of people living with AFib, stroke risk is a major concern. The team at Laminar is driven by our vision to develop and deliver an innovative solution to help patients live without the fear of stroke, or the need for long-term use of blood thinners,” Randy Lashinski, president and CEO of Laminar told the press. “We are looking forward to advancing this vision as part of Johnson & Johnson MedTech.”
“We are excited to welcome Laminar to Johnson & Johnson MedTech,” added Jasmina Brooks, president of Biosense Webster. “Laminar’s innovative approach will provide Biosense Webster the opportunity to expand our portfolio in this high growth market, complement our electrophysiology and Intracardiac Echo strengths, and deepen our presence with interventional cardiologists and electrophysiologists. Fueled by the global scale and commercial and clinical strength of Biosense Webster, we are excited to explore the possibilities ahead to reach even more patients with critical unmet need.”